Revolution Medicines
3 articles
Industry NewsRevolution MedicinesBioSpace
Revolution Medicines books $198M in first five weeks of Rasonque sales
- Rasonque, approved in late August for previously treated metastatic pancreatic cancer, generated $198M in Q3 sales, far above analyst forecasts of $19M to $100M.
- More than 5,000 patients were reached, helped by early-access conversions; management says it is too early to judge the steady-state trajectory.
- Revolution reported a $407.5M quarterly net loss and $3.7B in cash, while Phase 3 first-line trials continue to advance.
A $198M first quarter in a second-line pancreatic indication, part of it a one-time early-access conversion bump, says less about steady state than about unmet need: few drugs target RAS this directly. The real prize is first-line, where the Phase 3s and zoldonrasib sit. With $3.7B in cash, Revolution can fund that fight, and the bigger-pharma suitors will be watching.
Industry NewsIncyte / Revolution MedicinesBioSpace
Incyte's G12D Inhibitor Posts 89% Response With FOLFIRINOX in Pancreatic Cancer
- In a Phase 1 study of 54 metastatic pancreatic cancer patients, Incyte's KRAS G12D inhibitor plus mFOLFIRINOX produced an 89% confirmed response rate; with gemcitabine/nab-paclitaxel it was 69%.
- Safety was described as manageable and in line with chemotherapy alone.
- Analysts see it as competitive with Revolution Medicines' zoldonrasib (82% and 61% in comparable regimens); a first-line Phase 3 is underway.
A 7-point gap over zoldonrasib's 82% in the FOLFIRINOX setting is noise in a cross-trial comparison of a 54-patient Phase 1. The real signal is that Incyte is now a credible second contender in G12D pancreatic cancer, not a leader. With a first-line Phase 3 already running, progression-free survival and tolerability will decide the race, and this readout doesn't answer either.
Industry NewsRevolution MedicinesSTAT News
European regulators recommend Revolution Medicines' Rasonque for pancreatic cancer
- Following FDA approval, European regulators have recommended approval of Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer, per STAT+.
- The recommendation moves the RAS(ON) inhibitor toward a second major market.
- This summary rests on the article's teaser; a separate search could not confirm the EU opinion.
If confirmed, a quick EU follow-on after the US nod shows how fast an oral RAS(ON) inhibitor with a clear survival benefit in a deadly cancer can move. For analysts the questions now shift to pricing, reimbursement and label expansion beyond second-line pancreatic disease. It also validates the tri-complex approach for peers still chasing KRAS in the same tumor type.